Pharvaris N.V. Files Routine 6-K Report
Ticker: PHVS · Form: 6-K · Filed: Sep 23, 2024 · CIK: 1830487
| Field | Detail |
|---|---|
| Company | Pharvaris N.V. (PHVS) |
| Form Type | 6-K |
| Filed Date | Sep 23, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 6-K, disclosure, compliance
TL;DR
Pharvaris N.V. filed a routine 6-K, no major news.
AI Summary
Pharvaris N.V. filed a Form 6-K on September 23, 2024, for the month of September 2024. The company, a foreign private issuer, is based in Leiden, The Netherlands, and operates in the Pharmaceutical Preparations industry. This filing is routine and does not appear to contain specific financial updates or material events.
Why It Matters
This filing is a standard disclosure for foreign private issuers and typically indicates ongoing compliance rather than new material information.
Risk Assessment
Risk Level: low — The filing is a standard, periodic report for a foreign private issuer and does not contain any new material information that would typically impact risk.
Key Players & Entities
- Pharvaris N.V. (company) — Filer of the 6-K report
- 001-40010 (company) — Commission File Number for Pharvaris N.V.
- 2834 (company) — Standard Industrial Classification code for Pharmaceutical Preparations
FAQ
What type of filing is this?
This is a Form 6-K report of Foreign Private Issuer.
Who is the filer?
The filer is Pharvaris N.V.
What is the period this report covers?
The report is for the month of September 2024.
Where is Pharvaris N.V. located?
Pharvaris N.V. is located at Emmy Noetherweg 2, 2333 BK Leiden, The Netherlands.
Does Pharvaris N.V. file annual reports under Form 20-F or 40-F?
Pharvaris N.V. files annual reports under Form 20-F.
Filing Stats: 597 words · 2 min read · ~2 pages · Grade level 12.8 · Accepted 2024-09-23 06:51:03
Filing Documents
- 6-k_september_23.htm (6-K) — 22KB
- phvs-ex99_1.htm (EX-99.1) — 204KB
- 0000950170-24-108619.txt ( ) — 227KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PHARVARIS N.V. Date: September 23, 2024 By: /s/ Berndt Modig Name: Berndt Modig Title: Chief Executive Officer EXHIBIT INDEX Exhibit No. Description 99.1 Amendment 2, between Pharvaris Netherlands B.V. and AnalytiCon Discovery GmbH dated as of September 20, 2024, to the License Agreement between Pharvaris B.V. and AnalytiCon Discovery GmbH dated as of March 31, 2016.